A Randomized, Double-Blind, Placebo Controlled, Multicenter Phase 2a Study to Assess Safety, Daily Respiratory Symptoms, Pharmacokinetics, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs YPL 001 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Proof of concept
- Sponsors Yungjin Pharm Co
- 17 Aug 2017 Planned number of patients changed from 69 to 61.
- 17 Aug 2017 Planned End Date changed from 1 Jul 2017 to 31 Oct 2017.
- 17 Aug 2017 Planned primary completion date changed from 1 Feb 2017 to 31 Oct 2017.